Product Name: ErbB3 (1304-1310) pY1307
Product Number: PE-04AMD95
Size: 200 µg      Price:47.00
1 mg      $US94.00
5 mg      206.00
Peptide Name: ErbB3 (1304-1310) pY1307

Product Use: Services as a blocking peptide for use with the ErbB3-pY1307 rabbit polyclonal antibody (Cat. No.: AB-PK617) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the cytoplasmic region of ErbB3 near the C-terminus after the kinase catalytic domain. This is the major in vivo phosphorylation sites in ErbB3. The effect of its phosphorylation is unclear.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: HVH-pY-ARL

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys

Peptide Modifications Other: Phosphorylated

Peptide Molecular Mass Calculated: 1148.2 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: ErbB3 - pY1307 phosphosite-specific antibody (Cat. No.: AB-PK617)

Scientific Background: ErbB3 (HER3) is a protein-tyrosine kinase of the TK group and EGFR family. It is a receptor kinase that bind and be activated by NTAK and neuregulins. It has been proposed to be deficient in phosphotransferase activity. While the kinase domain appararently lacks activity but heterodimerizes with other EGFRs permits transduction of growth signals. Phosphorylation of Y1222 and Y1260 induces interaction with PIK3C and PIK3R1. ErbB3 appears to be up-regulated in many cancer, including medulloblastomas, verrucous carcinomas, childhood medulloblastomas, carotid body tumours (CBT), and gestational trophoblastic tumours (GTD).